Target LDL-C levels (according to global risk) were attained in 62% of atorvastatin recipients and 6% of bezafibrate recipients, and triglyceride levels <200 mg/dL were achieved in 52% and 60% of ...

Now, investigators have used serial intravascular ultrasound (IVUS) to track changes in plaque volume in a randomized comparison of rosuvastatin (40 mg daily) and atorvastatin (80 mg daily ...